Mirtazapine was significantly more effective than a serotonin-noradrenaline reuptake inhibitor ( venlafaxine only , two trials , n = 415 ) at two weeks ( OR 2.29 , 95 % CI 1.45 to 3.59 ) and at the end of acute-phase treatment ( OR 1.53 , 95 % CI 1.03 to 2.25).In terms of dropouts , there was no robust evidence to detect a difference between mirtazapine and other antidepressants .
Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction .
AUTHORS ' CONCLUSIONS Some statistically significant and possibly clinical ly meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression .
Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment .
Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants , although the adverse event profile of mirtazapine is unique
BACKGROUND Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice .
OBJECTIVES The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults .
Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
BACKGROUND A sustained-release formulation of bupropion ( bupropion SR ) , developed with an improved pharmacokinetic profile to permit less frequent dosing than the immediate-release form , has not been evaluated in active comparator trials . This r and omized , double-blind , parallel-group trial was conducted to compare the efficacy and safety of bupropion SR and sertraline . METHOD Out patients with moderate to severe major depressive disorder ( DSM-IV ) received bupropion SR ( 100 - 300 mg/day ) or sertraline ( 50 - 200 mg/day ) for 16 weeks . Psychiatric evaluations , including the Hamilton Rating Scale for Depression ( HAM-D ) , the Hamilton Rating Scale for Anxiety ( HAM-A ) , the Clinical Global Impressions scale for Severity of Illness ( CGI-S ) , and for Improvement ( CGI-I ) were completed , and adverse events were assessed in the clinic periodically throughout treatment . Patients ' orgasm function was also assessed . RESULTS Mean HAM-D , HAM-A , CGI-I , and CGI-S scores improved over the course of treatment in both the bupropion SR group and the sertraline group ; no between-group differences were observed on any of the scales . Orgasm dysfunction was significantly ( p < .001 ) more common in  sertraline-treated patients compared with bupropion SR-treated patients . The adverse events of nausea , diarrhea , somnolence , and sweating were also experienced more frequently ( p < .05 ) in sertraline-treated patients . No differences were noted between the two treatments for vital signs and weight . CONCLUSION This double-blind comparison of bupropion SR and sertraline demonstrates that bupropion and sertraline are similarly effective for the treatment of depression . Both compounds were relatively well tolerated , and orgasm dysfunction , nausea , diarrhea , somnolence , and sweating were reported more frequently in sertraline-treated patients
Mirtazapine was significantly more effective than a serotonin-noradrenaline reuptake inhibitor ( venlafaxine only , two trials , n = 415 ) at two weeks ( OR 2.29 , 95 % CI 1.45 to 3.59 ) and at the end of acute-phase treatment ( OR 1.53 , 95 % CI 1.03 to 2.25).In terms of dropouts , there was no robust evidence to detect a difference between mirtazapine and other antidepressants .
Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction .
AUTHORS ' CONCLUSIONS Some statistically significant and possibly clinical ly meaningful differences between mirtazapine and other antidepressive agents were found for the acute-phase treatment of major depression .
Mirtazapine is likely to have a faster onset of action than SSRIs during the acute-phase treatment .
Dropouts occur similarly in participants treated with mirtazapine and those treated with other antidepressants , although the adverse event profile of mirtazapine is unique
BACKGROUND Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice .
OBJECTIVES The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults .